Erbitux Phase IV Studies Will Evaluate EGFR Expression As Patient Selection Criterion
This article was originally published in The Pink Sheet Daily
Executive Summary
Two of 13 total postmarketing commitments involve studying the efficacy of Erbitux in patients with EGFR-negative colorectal cancer. Other Phase IVs include a dose finding study in the pediatric population.